A number of other analysts also recently issued reports on CATB. Cowen and Company reaffirmed a buy rating on shares of Catabasis Pharmaceuticls in a report on Wednesday, June 8th. Zacks Investment Research raised Catabasis Pharmaceuticls from a hold rating to a buy rating and set a $4.25 price target for the company in a report on Tuesday, July 5th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Catabasis Pharmaceuticls has a consensus rating of Buy and a consensus price target of $19.05.
Catabasis Pharmaceuticls (NASDAQ:CATB) traded down 2.2384% during midday trading on Thursday, reaching $6.1101. The company’s stock had a trading volume of 1,312,902 shares. The stock’s 50-day moving average price is $4.69 and its 200 day moving average price is $4.78. The firm’s market capitalization is $93.98 million. Catabasis Pharmaceuticls has a 1-year low of $3.31 and a 1-year high of $10.83.
Catabasis Pharmaceuticls (NASDAQ:CATB) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.04. Equities analysts anticipate that Catabasis Pharmaceuticls will post ($2.47) EPS for the current fiscal year.
An institutional investor recently bought a new position in Catabasis Pharmaceuticls stock. Bridgeway Capital Management Inc. bought a new stake in shares of Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 27,700 shares of the company’s stock, valued at approximately $102,000. Bridgeway Capital Management Inc. owned approximately 0.18% of Catabasis Pharmaceuticls at the end of the most recent reporting period. Institutional investors own 66.58% of the company’s stock.
Catabasis Pharmaceuticls Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related companies with MarketBeat.com's FREE daily email newsletter.